{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-037511","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.183471+00:00","generated_at":"2026-05-31T09:10:56.708904+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment","bullets":["FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.","Approval based on Phase 3 CIDS trial and additional pediatric data from earlier studies.","Target customer base expands to approximately 20 pediatric burn centers in the U.S.","NexoBrid was previously approved for adults in December 2022; pediatric indication adds new revenue opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-037511","json":"https://secwatch.observer/filing/0001140361-24-037511.json","markdown":"https://secwatch.observer/filing/0001140361-24-037511.md","text":"https://secwatch.observer/filing/0001140361-24-037511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/0001140361-24-037511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/ef20034225_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:10:56.708904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}